Compare SII & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SII | SUPN |
|---|---|---|
| Founded | 2008 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.8B |
| IPO Year | 2011 | 2010 |
| Metric | SII | SUPN |
|---|---|---|
| Price | $126.34 | $41.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $132.00 | $61.60 |
| AVG Volume (30 Days) | 152.9K | ★ 511.5K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $392,755,000.00 |
| Revenue This Year | $26.03 | $22.70 |
| Revenue Next Year | $11.83 | $19.14 |
| P/E Ratio | $63.42 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $69.08 | $41.50 |
| 52 Week High | $169.63 | $59.68 |
| Indicator | SII | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 52.94 | 29.75 |
| Support Level | $124.54 | N/A |
| Resistance Level | $137.62 | $52.33 |
| Average True Range (ATR) | 4.30 | 1.28 |
| MACD | -0.96 | -0.38 |
| Stochastic Oscillator | 23.40 | 2.24 |
Sprott Inc is an alternative asset manager. The company has four reportable segments: Exchange Listed Products, which derives key revenue, and includes management services to the company's closed-end physical trusts and exchange-traded funds, both of which are actively traded on public securities exchanges; Managed equities segment provides asset management and sub-advisory services to the company's branded funds, fixed-term LPs and managed accounts; Private strategies which provide lending and streaming activities through limited partnership vehicles; and the Corporate segment which provides capital, balance sheet management and enterprise shared services to the company's subsidiaries. Geographically, it derives key revenue from Canada, followed by the United States.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.